Protagonist Therapeutics, Inc. (PTGX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PTGX Revenue Growth
Revenue Breakdown (FY 2024)
PTGX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PTGX Revenue Analysis (2014–2025)
As of May 8, 2026, Protagonist Therapeutics, Inc. (PTGX) generated trailing twelve-month (TTM) revenue of $17.7 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, PTGX's 5-year compound annual growth rate (CAGR) stands at +10.0%, indicating steady revenue expansion. The company achieved its highest annual revenue of $434.4 million in 2024.
Revenue diversification analysis shows PTGX's business is primarily driven by Development Services (100%). With over half of revenue concentrated in Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), PRTA (-58.0% YoY), and ACRS (-58.2% YoY), PTGX has underperformed the peer group in terms of revenue growth. Compare PTGX vs KYMR →
PTGX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PTGXCurrent | $18M | -100.0% | +10.0% | -343.6% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 ACRS | $8M | -58.2% | +3.8% | -975.9% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% |
PTGX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $46.0M | -89.4% | $44.8M | 97.3% | $-158,127,000 | -343.6% |
| 2024 | $434.4M | +624.1% | $434.4M | 100.0% | $252.8M | 58.2% |
| 2023 | $60.0M | +125.7% | $60.0M | 100.0% | $-93,652,000 | -156.1% |
| 2022 | $26.6M | -2.8% | $26.6M | 100.0% | $-131,373,000 | -494.2% |
| 2021 | $27.4M | -4.4% | $27.4M | 100.0% | $-125,845,000 | -460.0% |
| 2020 | $28.6M | +12293.1% | $28.6M | 100.0% | $-64,516,000 | -225.4% |
| 2019 | $231K | -99.3% | $231K | 100.0% | $-80,521,000 | -34857.6% |
| 2018 | $30.9M | +54.1% | $30.9M | 100.0% | $-42,269,000 | -136.7% |
| 2017 | $20.1M | - | $20.1M | 100.0% | $-37,897,000 | -188.9% |
| 2016 | $0 | - | $-317,000 | - | $-32,666,000 | - |
See PTGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTGX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTGX — Frequently Asked Questions
Quick answers to the most common questions about buying PTGX stock.
Is PTGX's revenue growth accelerating or slowing?
PTGX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +10.0%. TTM revenue fell to $18M. This reverses the prior growth trend.
What is PTGX's long-term revenue growth rate?
Protagonist Therapeutics, Inc.'s 5-year revenue CAGR of +10.0% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is PTGX's revenue distributed by segment?
PTGX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.